📊 INVA Key Takeaways
Is Innoviva, Inc. (INVA) a Good Investment?
Innoviva demonstrates exceptional financial health with extraordinary revenue growth of 1,851% YoY and an exceptional net margin of 65.9%, indicating highly profitable operations. The company maintains fortress-like liquidity with a 14.64x current ratio, minimal leverage (0.22x debt-to-equity), and generates robust free cash flow of $195.8M representing 47.6% of revenue, providing substantial financial flexibility and capital deployment capacity.
Innoviva shows very strong underlying fundamentals, with high gross, operating, and net margins, substantial free cash flow generation, and an unusually strong liquidity position. The balance sheet appears conservative with low leverage, but the mismatch between explosive revenue growth and flat net income suggests investors should scrutinize earnings quality, mix shifts, and whether recent growth is sustainable.
Why Buy Innoviva, Inc. Stock? INVA Key Strengths
- Extraordinary revenue growth of 1,851% YoY signals major commercial success or product launch
- Industry-leading profitability with 65.9% net margin and 74.8% gross margin indicating pricing power and operational efficiency
- Exceptional cash generation with $195.8M free cash flow and 47.6% FCF margin providing strong organic funding capability
- Fortress balance sheet with $550.9M cash, 0.22x debt-to-equity ratio, and 14.64x current ratio demonstrating financial strength
- Strong return metrics with 23.1% ROE and 16.6% ROA indicating efficient capital deployment
- Minimal capital intensity with capex only $1.1M supporting high-margin pharmaceutical business model
- Exceptional profitability with 74.8% gross margin, 39.8% operating margin, and 65.9% net margin
- Strong financial health supported by $550.94M in cash, very high current and quick ratios, and modest debt-to-equity of 0.22x
- High cash conversion with $195.80M of free cash flow and a 47.6% FCF margin
INVA Stock Risks: Innoviva, Inc. Investment Risks
- Extreme revenue growth of 1,851% YoY suggests potential one-time event, revenue anomaly, or unsustainable spike requiring investigation into drivers
- Pharmaceutical sector regulatory and patent cliff risks could impact revenue sustainability if growth driven by single product
- Limited visibility into revenue composition and customer concentration; disproportionate reliance on single product or customer could explain volatility
- Flat net income growth (0% YoY) despite massive revenue increase suggests significant margin compression or one-time charges requiring clarification
- 3 insider Form 4 filings in last 90 days warrant monitoring for potential insider concerns
- Revenue surged 1850.7% YoY while net income was flat, which may indicate acquisition effects, non-recurring items, or weaker incremental earnings quality
- Pharmaceutical earnings can be vulnerable to product concentration, royalty cliffs, regulatory events, and pipeline execution risk
- Interest coverage is solid at 9.8x but should still be monitored if operating performance weakens or financing costs rise
Key Metrics to Watch
- Revenue sustainability and composition - validate whether 1,851% growth represents sustainable demand or one-time event
- Gross margin trend - monitor for margin compression that would indicate pricing pressure or unfavorable product mix shift
- Operating cash flow conversion - ensure net income growth aligns with operating cash flow to validate earnings quality
- Debt levels and leverage ratios - track if company maintains conservative capital structure given growth phase
- Product pipeline and patent expiration dates - critical for pharmaceutical sector revenue sustainability
- Net income and operating cash flow growth relative to revenue growth
- Gross margin stability and revenue concentration by product/royalty source
Innoviva, Inc. (INVA) Financial Metrics & Key Ratios
💡 AI Analyst Insight
The 47.6% free cash flow margin provides substantial flexibility for dividends, buybacks, and strategic investments. Strong liquidity with a 14.64x current ratio provides a solid financial cushion.
INVA Profit Margin, ROE & Profitability Analysis
INVA vs Healthcare Sector: How Innoviva, Inc. Compares
How Innoviva, Inc. compares to Healthcare sector averages
Sector benchmarks are approximate industry averages. Actual sector performance may vary.
Is Innoviva, Inc. Stock Overvalued? INVA Valuation Analysis 2026
Based on fundamental analysis, Innoviva, Inc. appears fundamentally strong relative to the Healthcare sector in 2026.
Note: This is a fundamental analysis based on SEC filings. For P/E ratio, price targets, and market-based valuation, consult financial data providers. This is not investment advice.
Innoviva, Inc. Balance Sheet: INVA Debt, Cash & Liquidity
INVA Revenue & Earnings Growth: 5-Year Financial Trend
5-Year Trend Summary: Innoviva, Inc.'s revenue has shown modest growth of 5% over the 5-year period. The most recent EPS of $2.20 reflects profitable operations.
INVA Revenue Growth, EPS Growth & YoY Performance
INVA Quarterly Earnings & Performance
| Quarter | Revenue | Net Income | EPS |
|---|---|---|---|
| Q3 2025 | $89.5M | $1.2M | $0.02 |
| Q2 2025 | $99.9M | $1.8M | $0.03 |
| Q1 2025 | $77.5M | $36.5M | $0.46 |
| Q3 2024 | $67.3M | $1.2M | $0.02 |
| Q2 2024 | $81.0M | $1.3M | $0.02 |
| Q1 2024 | $76.4M | $34.9M | $0.42 |
| Q3 2023 | $67.3M | $1.3M | $0.98 |
| Q2 2023 | $81.0M | $1.3M | $0.02 |
Data sourced from SEC EDGAR 10-Q quarterly filings. Figures may represent quarterly or cumulative values.
Innoviva, Inc. Dividends, Buybacks & Capital Allocation
INVA SEC Filings: Latest 10-K & 10-Q Analysis
Access official SEC EDGAR filings for Innoviva, Inc. (CIK: 0001080014)
📋 Recent SEC Filings
❓ Frequently Asked Questions about INVA
What is the AI rating for INVA?
Innoviva, Inc. (INVA) has a Combined AI Rating of BUY from Claude (STRONG BUY) and ChatGPT (BUY) with 88% combined confidence, based on fundamental analysis of SEC EDGAR filings.
What are INVA's key strengths?
Claude: Extraordinary revenue growth of 1,851% YoY signals major commercial success or product launch. Industry-leading profitability with 65.9% net margin and 74.8% gross margin indicating pricing power and operational efficiency. ChatGPT: Exceptional profitability with 74.8% gross margin, 39.8% operating margin, and 65.9% net margin. Strong financial health supported by $550.94M in cash, very high current and quick ratios, and modest debt-to-equity of 0.22x.
What are the risks of investing in INVA?
Claude: Extreme revenue growth of 1,851% YoY suggests potential one-time event, revenue anomaly, or unsustainable spike requiring investigation into drivers. Pharmaceutical sector regulatory and patent cliff risks could impact revenue sustainability if growth driven by single product. ChatGPT: Revenue surged 1850.7% YoY while net income was flat, which may indicate acquisition effects, non-recurring items, or weaker incremental earnings quality. Pharmaceutical earnings can be vulnerable to product concentration, royalty cliffs, regulatory events, and pipeline execution risk.
What is INVA's revenue and growth?
Innoviva, Inc. reported revenue of $411.3M.
Does INVA pay dividends?
Innoviva, Inc. does not currently pay dividends.
Where can I find INVA SEC filings?
Official SEC filings for Innoviva, Inc. (CIK: 0001080014) including 10-K, 10-Q, and 8-K reports are available on SEC EDGAR.
What is INVA's EPS?
Innoviva, Inc. has a diluted EPS of $3.30.
How is the AI analysis conducted?
Two independent AI systems — Claude (Anthropic) and ChatGPT (OpenAI) — analyze SEC EDGAR filings including 10-K annual reports and 10-Q quarterly reports. Each AI evaluates financial health, profitability ratios, balance sheet strength, and growth metrics. The combined rating reflects both perspectives for balanced insights.
Is INVA a good stock to buy right now?
Based on our AI fundamental analysis in April 2026, Innoviva, Inc. has a BUY rating with 88% confidence. The AI analysis suggests favorable fundamentals based on SEC filings. This is not investment advice.
Is INVA stock overvalued or undervalued?
Valuation metrics for INVA: ROE of 23.1% (sector avg: 15%), net margin of 65.9% (sector avg: 12%). Higher ROE suggests strong returns relative to peers.
Should I buy INVA stock in 2026?
Our dual AI analysis gives Innoviva, Inc. a combined BUY rating for 2026. Revenue is data pending, with profitability above sector average. Always conduct your own research.
What is INVA's free cash flow?
Innoviva, Inc.'s operating cash flow is $196.9M, with capital expenditures of $1.1M. FCF margin is 47.6%.
How does INVA compare to other Healthcare stocks?
Vs Healthcare sector averages: Net margin 65.9% (avg: 12%), ROE 23.1% (avg: 15%), current ratio 14.64 (avg: 2).